Terns Pharmaceuticals Inc. (TERN) Appoints Heather Turner to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Wall St edges lower as chips fall; markets assess big bank earnings
- Oil prices ease as US-Russia diesel deal hopes offset Middle East attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- CoreWeave stock drops on insider selling notice
- Sysco calls on Teamsters to end LA strike after economic deal reached
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
November 18, 2024 4:05 PM ESTAccomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience
FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Companys Board of Directors, effective immediately. In conjunction with Ms. Turners appointment, Ann E. Taylor, M.D., is stepping down from the Board of... More



